Adults

One tablet once daily, preferably at the same time each day. Dosage may be adjusted based on individual response and tolerability.

Elderly

No specific dosage adjustment is generally required, but caution is advised due to potential for increased sensitivity.

Renal_impairment

No dosage adjustment necessary for mild to moderate renal impairment. Caution with severe impairment.

Onset

Amlodipine: 6-12 hours for antihypertensive effect. Atorvastatin: Lipid-lowering effects within 2 weeks, maximal by 4 weeks.

Excretion

Amlodipine: Primarily excreted in urine as inactive metabolites. Atorvastatin: Primarily excreted in bile as metabolites.

Half life

Amlodipine: 30-50 hours. Atorvastatin: Approximately 14 hours (20-30 hours for HMG-CoA reductase inhibitory activity due to active metabolites).

Absorption

Amlodipine: Well absorbed, bioavailability 64-90%, peak plasma levels 6-12 hours. Atorvastatin: Rapidly absorbed, bioavailability approximately 12% due to first-pass metabolism, peak plasma levels 1-2 hours.

Metabolism

Amlodipine: Extensively metabolized in the liver to inactive metabolites. Atorvastatin: Extensively metabolized by CYP3A4 to active and inactive metabolites.

CYP3A4 Inducers (e.g., Rifampicin)

May decrease plasma concentrations of Amlodipine and Atorvastatin, reducing their efficacy.

Cyclosporine, Gemfibrozil, Niacin, Colchicine

Increased risk of myopathy/rhabdomyolysis when co-administered with Atorvastatin.

CYP3A4 Inhibitors (e.g., Ketoconazole, Diltiazem, Macrolides, Protease Inhibitors)

Can increase plasma concentrations of both Amlodipine and Atorvastatin, increasing risk of side effects like myopathy/rhabdomyolysis for Atorvastatin.